Related Experiment Video

Updated: Jul 10, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Controlled release systems of angiogenic growth factors for cardiovascular diseases

Jiro Esaki1, Akira Marui, Yasuhiko Tabata

  • 1Kyoto University Graduate School of Medicine, Department of Cardiovascular Surgery, 54 Kawara, Shogoin, Sakyo, Kyoto 606-8507, Japan.

Expert Opinion on Drug Delivery
|November 1, 2007
PubMed

Insights

Therapeutic angiogenesis offers a promising alternative for patients with myocardial and limb ischemia when traditional treatments fail. This review explores growth factor clinical trials and a novel hydrogel delivery system.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Biomaterials Science

Background:

  • Increasing prevalence of myocardial and limb ischemia due to aging and atherosclerosis.
  • Limitations of current treatments (medical, angioplasty, surgery) for severe cases.
  • Therapeutic angiogenesis emerges as a potential alternative therapy.

Purpose of the Study:

  • To review clinical trials of angiogenic growth factors for myocardial and limb ischemia.
  • To introduce a novel controlled release system for growth factors.
  • To highlight advancements in treating ischemic diseases.

Main Methods:

  • Review of clinical trials involving angiogenic growth factors.
  • Description of a novel gelatin hydrogel for controlled growth factor delivery.
  • Analysis of therapeutic angiogenesis strategies.

Main Results:

  • Growth factors show potential in treating myocardial and limb ischemia.
  • Controlled release systems can improve therapeutic efficacy.
  • Gelatin hydrogel offers a promising delivery platform.

Conclusions:

  • Therapeutic angiogenesis is a viable option for refractory ischemic diseases.
  • Novel delivery systems enhance the potential of growth factor therapy.
  • Further research is warranted to optimize these approaches.

More Related Videos

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair09:34

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair

Published on: September 7, 2017

The Aortic Ring Co-culture Assay: A Convenient Tool to Assess the Angiogenic Potential of Mesenchymal Stromal Cells In Vitro10:04

The Aortic Ring Co-culture Assay: A Convenient Tool to Assess the Angiogenic Potential of Mesenchymal Stromal Cells In Vitro

Published on: September 18, 2017

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: